INTERIM REPORT JANUARY - MARCH 2016

FIRST QUARTER

  · Net sales amounted to MSEK 82.3 (0.4)
  · Earnings before depreciation were MSEK 9.3 (-14.9)
  · Earnings per share amounted to SEK 0.06 (-0.42)
  · Cash and cash equivalents at period end amounted to MSEK 11.2 (32.2)
  · The name of the Group was changed to Karo Pharma to better re-flect current
operations

SIGNIFICANT EVENTS AFTER PERIOD END

  · Two share issues totaling MSEK 280 were carried out. The issues, which were
oversubscribed by 210 per cent, were completed after period end, hence not being
reflected in the cash position. Executive Chairman Anders Lönner underwrote over
97 percent of the rights issue of MSEK 250.

CONFERENCE CALL / AUDIOCAST TODAY AT 10.00 A.M. CET
A presentation of the report (in Swedish) will take place today at 10 a.m. The
presentation and slides are available through the corporate website
www.karopharma.se or by telephone 08-505 564 74. Questions may be submitted over
the internet or by the telephone.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Henrik Palm, CFO, +46 70 540 4014 or henrik.palm@karopharma.se
ABOUT KARO PHARMA
Karo Pharma is a healthcare company that develops and markets products to
pharmacies and directly to healthcare providers. The share is listed on Nasdaq
Stockholm.
The information in this report is such that Karo Pharma is required to disclose
under the Swedish Securi-ties Market Act. The information was disclosed on May
12, 2016 at 8.30 a.m. CET.